Exelixis and Daiichi Report Launch of Minnebro (Esaxerenone) Tablets for Hypertension in Japan

 Exelixis and Daiichi Report Launch of Minnebro (Esaxerenone) Tablets for Hypertension in Japan

Exelixis and Daiichi Report Launch of Minnebro (Esaxerenone) Tablets for Hypertension in Japan

Shots:

  • The approval of Minnebro (Esaxerenone) tablets (1.25/2.5/5 mg) is based on P-III ESAX-HTN study in patients with hypertension, with its regulatory approval submitted to MHLW in Feb’18
  • In Q2’19, Exelixis will receive $20M as milestone payment from Daiichi, as per their research collaboration for the development of therapies targeting mineralocorticoid receptor signed in 2006
  • Minnebro (Esaxerenone) tablets are mineralocorticoid receptor blocker targeted to treat patients with hypertension, and is currently evaluated in P-III ESAX-DN study for patients with diabetic nephropathy by Daiichi in Japan

Click here to read full press release/ article | Ref: Exelixis | Image: Brand Navigation

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post